Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Price:
5.72
CNY
-1.89%
Market Cap:
¥38B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
CN |
|
Ichia Technologies Inc
TWSE:2402
|
TW |
|
Rarex Ltd
ASX:REE
|
AU |
|
S
|
Sweet Poison Spirits Inc
CNSX:SPS
|
CA |
|
Medicenna Therapeutics Corp
TSX:MDNA
|
CA |
|
A
|
Allianz Malaysia Bhd
KLSE:ALLIANZ
|
MY |
|
B
|
Bambuser AB
STO:BUSER
|
SE |
|
Academy Sports and Outdoors Inc
NASDAQ:ASO
|
US |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
US |
|
Independent Bank Corp (Michigan)
NASDAQ:IBCP
|
US |
|
Arcticzymes Technologies ASA
OSE:AZT
|
NO |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
Indra Sistemas SA
F:IDA
|
ES |
|
Sayona Mining Ltd
ASX:SYA
|
AU |
Multiples-Based Value
The
Multiples-Based Value for
Shanghai RAAS Blood Products Co Ltd (002252)
under the Base Case is
hidden
CNY.
Compared with the current market price of 5.72 CNY, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Shanghai RAAS Blood Products Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Shanghai RAAS Blood Products Co Ltd Competitors
Shanghai RAAS Blood Products Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
38B CNY | 5.2 | 24.1 | 25.4 | 25.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
375.5B USD | 6.1 | 89.7 | 14.8 | 20.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.7B USD | 5.2 | 24.8 | 14.4 | 14.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
176.3B USD | 6 | 20.7 | 12.9 | 16 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.5B USD | 9.5 | 28.7 | 21.6 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.2B USD | 5.7 | 18 | 13.5 | 15.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | 40.9 | 41.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD | 3 | 32.7 | 11 | 13.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
